Nima Nabavizadeh, MD, Oregon Health & Science University, Portland, OR, discusses the PATHFINDER II study (NCT05155605), evaluating a multi-cancer early...

YD Bio (NasdaqGM: YDES) announced support for U.S. access to OkaiDx™, a cfDNA‑methylation blood test for post‑treatment breast cancer monitoring, now available through affiliate EG BioMed’s CLIA/CAP‑certified laboratory as a research‑use‑only (RUO) assay.The company will coordinate commercialization, researcher engagement and sample logistics to enable testing for research laboratories, academic groups and industry partners. Independent validation reported 95.1% accuracy, 89.4% sensitivity and 96.5% specificity. OkaiDx™ is not FDA cleared and is not intended to diagnose, treat, cure or prevent disease.

Join us at ISLB 2025, the 7th Annual Congress of Liquid Biopsy, in Orlando, Florida, from November 1-3, 2025.

Acute rejection, one of the most devastating complications that can occur following organ transplantation, is caused by antigenic differences between the organ donor and the recipient. Following cardi...

In October's ISHLT Journal Watch, transplant pathologists review recent literature on dd-cf-DNA, CAV, and ALAD.

Cell Death Discovery - Nanopore sequencing enables tissue-of-origin and pathogen detection in plasma cell-free DNA from critically ill patients

A recent NGS study in patients with MDS demonstrated that molecular as well as cytogenetic abnormalities in cfDNA from peripheral blood mirror the profile in bone marrow. Such results give further support to a promising option of testing cf...

Background Cell-free DNA (cfDNA), derived from dying cells, has demonstrated utility across multiple clinical applications. However, its potential in neurodegenerative diseases remains underexplored, ...